Valganciclovir for the Suppression of Epstein-Barr Virus Replication.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 28838145.
- Also identified by DOI 10.1093/infdis/jix263 and PMC identifier 5854009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative treatment. Valganciclovir reduced the proportion of days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.41; P < .001), and quantity of virus detected by 0.77 logs (95% CI, .62-.91 logs; P < .001). Further investigations into the impact of valganciclovir on EBV-associated diseases are needed.
Medical subject headings
- Antiviral Agents
- Ganciclovir
- Infectious Mononucleosis
- Virus Replication
- Virus Shedding